Skip to main content
Premium Trial:

Request an Annual Quote

Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing

NEW YORK – Natera and Personalis said on Wednesday that they are partnering on cancer treatment monitoring and molecular residual disease (MRD) testing.

Under the non-exclusive agreement, Natera will use matched tumor and normal exome sequencing data generated by Personalis to validate the design of its Signatera personalized circulating tumor DNA assays. The deal covers MRD testing for both clinical and research use and Natera will be responsible for commercializing the assays.

Personalis offers the NeXT Exome, which enhances conventional exome assays by adding coverage across coding regions and by including additional genomic regions.

"This represents another step forward in Natera's vision for Signatera, as a personalized monitoring and MRD platform that can be scaled and integrated robustly with high-quality, exome-scale tissue sequencing assays worldwide, of which Personalis' NeXT is a leading example," Solomon Moshkevich, Natera's general manager of oncology, said in a statement, adding that Natera hopes to expand access to Signatera to a new set of customers through the deal.

Financial and other terms of the agreement were not disclosed.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.